Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25250811 | 0.86 | EGFR (0.48) | EGFR | |
| SCHEMBL25373726 | 0.86 | EGFR (0.48) | EGFRMAPTHTTCYP1A2 | |
| SCHEMBL25662634 | 0.84 | EGFR (0.49) | EGFRMAPTHTT | |
| SCHEMBL27923390 | 0.81 | EGFR (0.67) | EGFRMAPT | |
| SCHEMBL25216766 | 0.81 | EGFR (0.56) | EGFR | |
| SCHEMBL29382670 | 0.81 | EGFR (0.46) | EGFR | |
| SCHEMBL25211108 | 0.81 | EGFR (0.46) | EGFR | |
| SCHEMBL26058048 | 0.80 | EGFR (0.43) | EGFRMAPTHTT | |
| SCHEMBL8870749 | 0.80 | ALDH1A1 (0.60) | EGFRALDH1A1MAPTLMNAKMT2A | |
| SCHEMBL26055501 | 0.78 | EGFR (0.51) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115803325-B | EGFR inhibitor and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4194443-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| EP-4194443-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| CN-115803325-A | EGFR inhibitor and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022033410-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271936-A1 | EFGR INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | EGFR, WEE1, WEE2 | EGFR 1/4885ALDH1A1 2368/4885MAPT 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.